用肝脏影像报告和数据系统2017版评估 explant 肝脏中肝细胞癌的治疗反应
本回顾性研究纳入114例患者206个肝细胞癌病灶,以肝移植标本为参考标准,比较LI-RADS v2017治疗反应算法与mRECIST预测局部治疗后肿瘤存活的效能。CT上LI-RADS的AUC显著高于mRECIST(0.733 vs 0.657,p<0.001),MRI上两者无显著差异(0.802 vs 0.791,p=0.500);使用LI-RADS时CT与MRI的AUC相当(0.783 vs 0.795,p=0.776)。
要点
- CT上LI-RADS v2017治疗反应算法的诊断效能优于mRECIST(AUC 0.733 vs 0.657,p<0.001)。
- MRI上LI-RADS与mRECIST的AUC无显著差异(0.802 vs 0.791,p=0.500)。
- 使用LI-RADS时,CT与MRI诊断肿瘤存活的AUC相当(0.783 vs 0.795,p=0.776)。
核心结论
- LI-RADS v2017治疗反应算法在CT上的诊断效能优于mRECIST;使用LI-RADS时,CT与MRI诊断局部治疗后肝细胞癌肿瘤存活的效能相当。
研究设计与样本
- 回顾性研究,纳入114例患者206个肝细胞癌病灶,均在接受局部治疗后行肝移植;以肝移植标本为参考标准;两名放射科医师分别独立使用LI-RADS和mRECIST在CT和MRI上评估肿瘤存活。
诊断标准与关键数值
- LI-RADS LR-TR存活标准为以下三项中任意一项:动脉期高强化(APHE)、廓清、与治疗前影像相似的强化模式;单独APHE与LR-TR存活标准诊断存活肿瘤的敏感度和特异度在CT(p=0.054和p=0.317)和MRI(p=0.093和p=0.603)上均无显著差异。
临床应用与阅片要点
- 作者结论认为,使用LI-RADS v2017治疗反应算法可准确诊断局部治疗后肝细胞癌的肿瘤存活;在CT上该算法优于mRECIST;使用该算法时CT或MRI均可用于评估肿瘤存活。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 treatment response algorithm for predicting hepatocellular carcinoma (HCC) viability after locoregional therapy (LRT) using the liver explant as reference.
METHODS: One hundred fourteen patients with 206 HCCs who underwent liver transplantation (LT) after LRT for HCCs were included in this retrospective study. Two radiologists independently evaluated tumor viability using the LI-RADS and modified RECIST (mRECIST) with CT and MRI, respectively. The sensitivity and specificity of arterial phase hyperenhancement (APHE) and LR-TR viable criteria (any of three findings: APHE, washout, and enhancement pattern similar to pretreatment imaging) were compared using logistic regression. Receiver operating characteristics (ROC) analysis was used to compare the diagnostic performance between LI-RADS and mRECIST and between CT and MRI.
RESULTS: The sensitivity and specificity for diagnosing viable tumor were not significantly different between APHE alone and LR-TR viable criteria on CT (p = 0.054 and p = 0.317) and MRI (p = 0.093 and p = 0.603). On CT, the area under the ROC curve (AUC) of LI-RADS was significantly higher than that of mRECIST (0.733 vs. 0.657, p < 0.001). On MRI, there was no significant difference in AUCs between LI-RADS and mRECIST (0.802 vs. 0.791, p = 0.500). Intra-individual comparison of CT and MRI showed comparable AUCs using LI-RADS (0.783 vs. 0.795, p = 0.776).
CONCLUSIONS: LI-RADS v2017 treatment response algorithm showed better diagnostic performance than mRECIST on CT. With LI-RADS, CT and MRI were comparable to diagnose tumor viability of HCC after LRT.
KEY POINTS: • Using Liver Imaging Reporting and Data System (LI-RADS) v2017 treatment response algorithm, the viability of hepatocellular carcinoma (HCC) after locoregional therapy (LRT) can be accurately diagnosed. • LI-RADS v2017 treatment response algorithm is superior to modified Response Evaluation Criteria in Solid Tumors for evaluating HCC viability using CT. • Either CT or MRI can be performed to assess tumor viability after LRT using LI-RADS v2017 treatment response algorithm.
引用
- Seo N, Kim MS, Park MS, et al. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017. Eur Radiol. 2019. PMID: 31418085. doi:10.1007/s00330-019-06376-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。